HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Effects of hormone therapy with estrogen and/or progesterone on sleep pattern in postmenopausal women.
OBJECTIVE To investigate the effects of estrogen and progesterone on sleep in postmenopausal women . METHOD The 33 participants were r and omly assigned to an estrogen or placebo group after undergoing clinical and hormonal assessment s and a polysomnogram , and they underwent the same tests again after 12 weeks . Then , while still taking estrogen or placebo , they all received progesterone for another 12 weeks and underwent a final polysomnogram . RESULTS Estrogen plus progesterone was more effective than estrogen alone in decreasing the prevalence of periodic limb movement ( PLM ) ( 8.1 % vs 2.8 % ) , hot flashes ( 14.2 % vs 0 % ) , and bruxism ( 11.1 % vs 0 % ) at night , or somnolence and attention difficulty during the day . The prevalences of breathing irregularities , arousal from sleep , anxiety , and memory impairment were decreased in both groups following progesterone treatment . CONCLUSION While not significantly affecting sleep quality , hormone therapy decreased the prevalence of arousal in both groups and that of PLM in the group treated with estrogen plus progesterone
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .